Literature DB >> 8806254

The statistical basis of public policy: a paradigm shift is overdue.

R J Lilford1, D Braunholtz.   

Abstract

The recent controversy over the increased risk of venous thrombosis with third generation oral contraceptives illustrates the public policy dilemma that can be created by relying on conventional statistical tests and estimates: case-control studies showed a significant increase in risk and forced a decision either to warn or not to warn. Conventional statistical tests are an improper basis for such decisions because they dichotomise results according to whether they are or are not significant and do not allow decision makers to take explicit account of additional evidence--for example, of biological plausibility or of biases in the studies. A Bayesian approach overcomes both these problems. A Bayesian analysis starts with a "prior" probability distribution for the value of interest (for example, a true relative risk)--based on previous knowledge--and adds the new evidence (via a model) to produce a "posterior" probability distribution. Because different experts will have different prior beliefs sensitivity analyses are important to assess the effects on the posterior distributions of these differences. Sensitivity analyses should also examine the effects of different assumptions about biases and about the model which links the data with the value of interest. One advantage of this method is that it allows such assumptions to be handled openly and explicitly. Data presented as a series of posterior probability distributions would be a much better guide to policy, reflecting the reality that degrees of belief are often continuous, not dichotomous, and often vary from one person to another in the face of inconclusive evidence.

Entities:  

Mesh:

Year:  1996        PMID: 8806254      PMCID: PMC2352073          DOI: 10.1136/bmj.313.7057.603

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  A Bayesian method for synthesizing evidence. The Confidence Profile Method.

Authors:  D M Eddy; V Hasselblad; R Shachter
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

2.  Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested.

Authors:  J E Buring; R J Glynn; C H Hennekens
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

Review 3.  The evolving concept of the healthy worker survivor effect.

Authors:  H M Arrighi; I Hertz-Picciotto
Journal:  Epidemiology       Date:  1994-03       Impact factor: 4.822

4.  Third generation oral contraception and venous thromboembolism.

Authors:  K McPherson
Journal:  BMJ       Date:  1996-01-13

5.  Equipoise and the ethics of randomization.

Authors:  R J Lilford; J Jackson
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

6.  Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals.

Authors:  K F Schulz; I Chalmers; D A Grimes; D G Altman
Journal:  JAMA       Date:  1994-07-13       Impact factor: 56.272

7.  Randomized versus historical controls for clinical trials.

Authors:  H Sacks; T C Chalmers; H Smith
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

8.  Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  M A Lewis; W O Spitzer; L A Heinemann; K D MacRae; R Bruppacher; M Thorogood
Journal:  BMJ       Date:  1996-01-13
  8 in total
  34 in total

Review 1.  Sifting the evidence-what's wrong with significance tests?

Authors:  J A Sterne; G Davey Smith
Journal:  BMJ       Date:  2001-01-27

Review 2.  Methods in health service research. An introduction to bayesian methods in health technology assessment.

Authors:  D J Spiegelhalter; J P Myles; D R Jones; K R Abrams
Journal:  BMJ       Date:  1999-08-21

Review 3.  Trials and fast changing technologies: the case for tracker studies.

Authors:  R J Lilford; D A Braunholtz; R Greenhalgh; S J Edwards
Journal:  BMJ       Date:  2000-01-01

4.  Prospective health impact assessment: pitfalls, problems, and possible ways forward.

Authors:  J Parry; A Stevens
Journal:  BMJ       Date:  2001-11-17

5.  Who's afraid of Thomas Bayes?

Authors:  R J Lilford; D Braunholtz
Journal:  J Epidemiol Community Health       Date:  2000-10       Impact factor: 3.710

6.  The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.

Authors:  Ben A van Hout; Dennis D Gagnon; Pauline McNulty; Anthony O'Hagan
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Likelihood ratio meta-analysis: New motivation and approach for an old method.

Authors:  Colin R Dormuth; Kristian B Filion; Robert W Platt
Journal:  Contemp Clin Trials       Date:  2016-02-04       Impact factor: 2.226

8.  Bayes' theorem: a negative example of a RCT on grommets in children with glue ear.

Authors:  Maroeska M Rovers; Gert Jan van der Wilt; Sjoukje van der Bij; Huub Straatman; Koen Ingels; Gerhard A Zielhuis
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

9.  Bayes and health care research.

Authors:  Peter Allmark
Journal:  Med Health Care Philos       Date:  2004

Review 10.  Cohort study design: an underutilized approach for advancement of evidence-based and patient-centered practice in athletic training.

Authors:  Gary B Wilkerson; Craig R Denegar
Journal:  J Athl Train       Date:  2014-06-16       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.